Abstract:SCN9A gene encodes voltage-gated sodium channel NaV1.7 and is associated with a group of heterogeneous phenotypes. Heterozygous gain-of-function SCN9A mutations have been linked to inherited erythromelalgia (IEM), paroxysmal extreme pain disorder (PEPD), and small-fiber neuropathy (SFN), while recessive loss-of-function SCN9A mutations have been linked to congenital insensitivity to pain (CIP). Recently, a heterozygous SCN9A mutation was found to be responsible for generalized epilepsy with febrile seizures plus (GEFS+) in a large pedigree.1 SCN9A variants have also been suggested as a genetic modifier in SCN1A mutation-associated GEFS+ and a possible susceptibility gene for Dravet syndrome [1Singh N.A. Pappas C. Dahle E.J. Claes L.R. Pruess T.H. De Jonghe P. et al.A role of SCN9A in human epilepsies, as a cause of febrile seizures and as a potential modifier of Dravet syndrome.PLoS Genet. 2009; 5: e1000649Crossref PubMed Scopus (209) Google Scholar, 2Mulley J.C. Hodgson B. McMahon J.M. Iona X. Bellows S. Mullen S.A. et al.Role of the sodium channel SCN9A in genetic epilepsy with febrile seizures plus and Dravet syndrome.Epilepsia. 2013; 54: e122-126Crossref PubMed Scopus (49) Google Scholar]. However, the exact role of SCN9A in seizure disorders is still complicated and debating [[2]Mulley J.C. Hodgson B. McMahon J.M. Iona X. Bellows S. Mullen S.A. et al.Role of the sodium channel SCN9A in genetic epilepsy with febrile seizures plus and Dravet syndrome.Epilepsia. 2013; 54: e122-126Crossref PubMed Scopus (49) Google Scholar]. We report a pedigree diagnosed as GEFS+ with a heterozygous mutation (Q10R) in SCN9A gene. The proband (III:1) was a six-year-old boy, who was born at term after an unremarkable pregnancy and had normal early psychomotor development. He experienced febrile and afebrile seizures for more than 10 times since the age of two. All the seizures presented as generalized tonic-clonic seizures for several minutes. No obvious abnormality was found on neurological examination. Brain MRI and ambulatory EEG were unremarkable. His younger brother (III:2) was two years old. He was also born at term after an unremarkable pregnancy and had normal early psychomotor development. He experienced febrile and afebrile seizures for 3 times at the age of two. In the further pedigree investigation, the proband’s mother (II:2) and grandmother (I:2) both reported febrile seizures in their childhood (Fig. 1). The febrile seizures of the mother (II:2) and grandmother (I:2) remitted spontaneously by the age of ten. There was no other symptom or sign found on the mother (II:2) and grandmother (I:2), except that both of them reported poor memory. To identify the causative gene of this GEFS+ pedigree, genetic test was performed on the proband using a Next-generation sequencing panel containing 480 epilepsy-related genes. A heterozygous missense mutation c.29A > G (p.Q10R) in SCN9A gene (reference transcript: NM_002977) was detected. This mutation was further confirmed by Sanger sequencing, detected in the affected mother (II:2) and brother (III:3), and not detected in the unaffected father (II:3) (Fig. 1) Interestingly, this missense mutation Q10R and another missense mutation in the same amino acid site − c.28C > A (p.Q10K) were previously reported as causative mutations of IEM patients. c.29A > G (p.Q10R) was absent in 200 alleles from normal Chinese controls, which supported it was unlikely to be a polymorphism [[3]Han C. Dib-Hajj S.D. Lin Z. Li Y. Eastman E.M. Tyrrell L. et al.Early- and late-onset inherited erythromelalgia: genotype-phenotype correlation.Brain. 2009; 132: 1711-1722Crossref PubMed Scopus (99) Google Scholar]. After follow-up questioning, none of these four patients (III:1, III:2, II:2 and I:2) reported any easily recognized extreme pain, warmth or redness phenotypes. Other genes associated with febrile seizures and GEFS+ like SCN1A, GABRG2, CPA6, GABRD and SCN1B were also included in the panel and no candidate mutation in these genes was detected. Based on these clinical symptoms, pedigree history and genetic analysis, we proposed that this is a GEFS+ pedigree associated with the Q10R mutation in SCN9A. Clinical heterogeneity is common in genetic diseases. Even affected members in a GEFS+ pedigree with the same SCN1A mutation could present different phenotypes from febrile seizures to Dravet syndrome, a severe epileptic encephalopathy. SCN9A associated phenotypes in human were varied and included IEM, PEPD, SFN and CIP. SCN9A encodes NaV1.7, which is mainly expressed in neurons of the dorsal root ganglia and has preliminarily been classified as a peripheral nervous system channel. However, expression of NaV1.7 in brain (embryonic hippocampal neurons) was also reported and suggested a role in the central nervous system [[4]Mechaly I. Scamps F. Chabbert C. Sans A. Valmier J. Molecular diversity of voltage-gated sodium channel alpha subunits expressed in neuronal and non-neuronal excitable cells.Neuroscience. 2005; 130: 389-396Crossref PubMed Scopus (61) Google Scholar]. A confirmed large pedigree of GEFS+ and several sporadic patients with febrile seizures associated with mutations in SCN9A were reported, which supported seizure disorders as a fifth phenotype of SCN9A. However, the reports about the role of SCN9A in seizure disorders were rare and still debating. Singh et al. suggested SCN9A as a potential modifier gene to Dravet syndrome in patients with SCN1A mutations [[1]Singh N.A. Pappas C. Dahle E.J. Claes L.R. Pruess T.H. De Jonghe P. et al.A role of SCN9A in human epilepsies, as a cause of febrile seizures and as a potential modifier of Dravet syndrome.PLoS Genet. 2009; 5: e1000649Crossref PubMed Scopus (209) Google Scholar]. Mulley et al. found that rare variants in SCN9A were significantly enriched in Dravet syndrome, but damaging variants were similar between Dravet syndrome patients and normal controls, which supported a role for SCN9A in genetic susceptibility to Dravet syndrome [[2]Mulley J.C. Hodgson B. McMahon J.M. Iona X. Bellows S. Mullen S.A. et al.Role of the sodium channel SCN9A in genetic epilepsy with febrile seizures plus and Dravet syndrome.Epilepsia. 2013; 54: e122-126Crossref PubMed Scopus (49) Google Scholar]. Although it seems complicated about the role of SCN9A in Dravet syndrome, the role of SCN9A in autosomal dominant febrile seizures or GEFS+ is simple. A large GEFS+ pedigree associated with SCN9A mutation with a quite high penetrance for about 95% was reported, which suggested a monogenic pattern in GEFS+ [[1]Singh N.A. Pappas C. Dahle E.J. Claes L.R. Pruess T.H. De Jonghe P. et al.A role of SCN9A in human epilepsies, as a cause of febrile seizures and as a potential modifier of Dravet syndrome.PLoS Genet. 2009; 5: e1000649Crossref PubMed Scopus (209) Google Scholar]. However, other febrile seizures or GEFS+ patients associated with SCN9A mutations were almost sporadic or only with one first-degree relative, which can not offer further powerful evidence for the role of SCN9A in autosomal dominant febrile seizures or GEFS+. We report a GEFS+ pedigree including four patients, which was associated with SCN9A mutation. This report further supports that SCN9A mutations are associated with GEFS+ with a monogenic pattern. Interestingly, the causative mutation in our pedigree Q10R and another mutation in the same amino acid site (Q10K) were reported in late-onset (age of 14 and 35 years) IEM patients [[3]Han C. Dib-Hajj S.D. Lin Z. Li Y. Eastman E.M. Tyrrell L. et al.Early- and late-onset inherited erythromelalgia: genotype-phenotype correlation.Brain. 2009; 132: 1711-1722Crossref PubMed Scopus (99) Google Scholar]. To our knowledge, there is no mutation in SCN9A associated with seizure disorders also found in IEM, PEPD, SFN or CIP patients previously. The underlying mechanism of such heterogeneity was still unclear. Functional study using current-clamp revealed that expression of Q10R mutation induced hyperexcitability on dorsal root ganglion neurons, and this increase in excitability was smaller than the change produced by an early-onset (usually before age of 6 years) IEM mutation I848T [[3]Han C. Dib-Hajj S.D. Lin Z. Li Y. Eastman E.M. Tyrrell L. et al.Early- and late-onset inherited erythromelalgia: genotype-phenotype correlation.Brain. 2009; 132: 1711-1722Crossref PubMed Scopus (99) Google Scholar]. A genotype-phenotype correlation was proposed that more increased excitability on dorsal root ganglion neurons was associated with earlier onset age of IEM. As SCN9A is also expressed in brain, we speculate that the Q10R mutation also increases the central nervous system excitability and causes the phenotype of seizure disorders. There may be a similar genotype-phenotype correlation that more increased central nervous system excitability is associated with more severe seizure disorders (from febrile seizures to Dravet syndrome). Although the mother and the grandmother were older than 30 years and 50 years respectively, no symptoms of IEM were complained so far. As the hyperexcitability on dorsal root ganglion neurons induced by Q10R was smaller than other mutation like I848T, reduced penetrance of IEM symptoms could be considered to explain the absence of IEM symptoms in our pedigree. On the other hand, most febrile seizures would remit spontaneously with age and might be missed by the IEM, PEPD, SFN and CIP patients and their doctors. It is suggested that IEM, PEPD, SFN and CIP patients with SCN9A mutations should be reinvestigated for their possible history of seizure disorders, which might help to further confirm the role of SCN9A in seizure disorders. This report expands the genotype-phenotype spectrum that the Q10R mutation in SCN9A gene is associated with both IEM and GEFS+, and it affects both peripheral and central nervous systems. The authors declare that they have no conflict of interest. We are indebted to the patient and parents for their generous participation in this study. This study was supported by the National Natural Science Foundation of China (Proj. No. 81600850).

Expanding the genotype-phenotype spectrum in SCN8A-related disorders

Variable epilepsy phenotypes associated with heterozygous mutation in the SCN9A gene: report of two cases

Clinical and Molecular Analysis of Epilepsy-Related Genes in Patients with Dravet Syndrome

Q10R Mutation in SCN9A Gene is Associated with Generalized Epilepsy with Febrile Seizures Plus

Genotype–phenotype associations in 1018 individuals with SCN1A‐related epilepsies

Expanded clinical phenotype spectrum correlates with variant function in SCN2A-related disorders

SCN1A-Related Epilepsy: Novel Mutations and Rare Phenotypes

SCN8A mutations in Chinese patients with early onset epileptic encephalopathy and benign infantile seizures

SCN1A‐related phenotypes: Epilepsy and beyond

SCN2A-Related Epilepsy: the Phenotypic Spectrum, Treatment and Prognosis

Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders

Phenotype Study of SCN2A Gene Related Epilepsy

The gain of function SCN1A disorder spectrum: novel epilepsy phenotypes and therapeutic implications

Insights into clinical phenotypes and treatment responses in a Small cohort of Taiwanese patients with SCN1A variants: A Preliminary study

A Case Report on SCN2A-Related Developmental and Epileptic Encephalopathy and Benign Familial Infantile Seizures

The Biallelic Inheritance of Two Novel SCN1A Variants Results in Developmental and Epileptic Encephalopathy Responsive to Levetiracetam

Resolution of SLC6A1 variable expressivity in a multi-generational family using deep clinical phenotyping and Drosophila models

A SCN8A variant associated with severe early onset epilepsy and developmental delay: Loss- or gain-of-function?

Novel Mutations and Phenotypes of Epilepsy-Associated Genes in Epileptic Encephalopathies.

Patients carrying pathogenic SCN8A variants with loss‐ and gain‐of‐function effects can be classified into five subgroups exhibiting varying developmental and epileptic components of encephalopathy

Biological concepts in human sodium channel epilepsies and their relevance in clinical practice